The Utility of Immunohistochemistry in Subtyping Adenocarcinoma of the Ampulla of Vater

被引:3
|
作者
Ang, Daphne C. [1 ]
Shia, Jinru [1 ]
Tang, Laura H. [1 ]
Katabi, Nora [1 ]
Klimstra, David S. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
关键词
intestinal adenocarcinoma; pancreatobiliary adenocarcinoma; histologic typing; interobserver variability; ADJUVANT CHEMOTHERAPY; CARCINOMA; PAPILLA; CLASSIFICATION; PANCREATICOBILIARY; DIFFERENTIATION; SURVIVAL; CANCER; ORIGIN;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Histologic classification of ampullary carcinomas into intestinal, pancreatobiliary, or other subtypes is easily achievable in some cases but difficult in others. Immunohistochemical (IHC) stains may allow distinction between the subtypes; however, their added value to routine hematoxylin and eosin (H&E) evaluation has not been systematically evaluated. Inconsistent histologic subtyping has hampered current clinical research and therapeutic trials. In this study, a consecutive series of 105 ampullary carcinomas was subtyped first by H&E evaluation and then by the evaluation of an IHC panel composed of CK7, CK20, CDX2, MUC1, and MUC2, and the added value of IHC was analyzed. By H&E, a consensus diagnosis, defined as concordant subtyping among at least 3 of the 4 independent study pathologists, was achieved in 81 of the 105 (77%) cases. There was excellent agreement for poorly differentiated and mucinous subtypes (kappa = 0.72 and 0.89, respectively) but only good agreement for intestinal and pancreatobiliary subtypes (kappa = 0.57 and 0.48, respectively) and poor agreement for mixed subtype (kappa = 0.09). By IHC, CK7 showed no informative value (being positive in >= 70% of the cases in both intestinal and pancreatobiliary subtypes), whereas a subtyping schema incorporating the combination staining patterns of CK20, CDX2, MUC1, and MUC2 did. By this schema, "intestinal subtype" was defined as having (1) positive staining for CK20 or CDX2 or MUC2 and negative staining for MUC1, or (2) positive staining for CK20, CDX2, and MUC2, irrespective of the MUC1 result; and "pancreatobiliary subtype" was defined as having positive staining for MUC1 and negative staining for CDX2 and MUC2, irrespective of CK20 results. Cases not fitting one of these 3 categories were regarded as "ambiguous" immunohistochemically. By combining this schema with H&E evaluation, 97 of the 105 cases (92%) could be classified into either intestinal or pancreatobiliary subtype. In particular, immunophenotyping allowed categorization of 75% of poorly differentiated adenocarcinomas and 69% of cases with mixed histologic features as either intestinal or pancreatobiliary subtype. Most mucinous adenocarcinomas (88%) were clearly intestinal subtype by IHC. Thus, our IHC schema enhanced the subtyping of ampullary carcinoma and, in combination with H&E evaluation, allowed a dichotomous classification in 92% of the cases. Should further independent studies reaffirm our findings, this schema may serve as a valuable tool in both diagnostic and research settings.
引用
收藏
页码:1371 / 1379
页数:9
相关论文
共 50 条
  • [31] Role of Immunohistochemistry in the Subtyping of Periampullary Adenocarcinoma
    Bakshi, Neha
    Dhawan, Shashi
    Nundy, Samiran
    Rao, Seema
    Chopra, Prem
    Bhalla, Sunita
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2019, 27 (06) : 598 - 608
  • [32] Ampulla of Vater adenocarcinoma in the Veteran's Affairs population
    Safa, M. M.
    Ahmed, K.
    Beg, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] The Role of Immunohistochemistry in Subtyping Ampullary Adenocarcinoma
    Costigan, Danielle
    Sheahan, Kieran
    Conlon, Kevin C.
    Geoghegan, Justin
    Hoti, Emir
    Maguire, Donal
    Traynor, Oscar
    O'Toole, Dermot
    Hayes, Miriam
    Burton, Emer
    Murphy, Jean
    Swan, Niall
    LABORATORY INVESTIGATION, 2016, 96 : 167A - 167A
  • [34] Adenocarcinoma of the Ampulla of Vater: A Case Report on a Rare Condition
    V. Kantode, Vaishnavi
    Sharma, Ranjana
    Wanjari, Mayur B.
    Munjewar, Pratiksha K.
    Tivaskar, Suhas P.
    Nakhale, Abhas
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [35] Adenocarcinoma of the ampulla of Vater: does the histopathologic type matter?
    Amptoulach, Sousana
    Josefsson, Axel
    Kavantzas, Nikolaos
    Kalaitzakis, Evangelos
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2011, 46 (11) : 1401 - 1403
  • [36] Molecular pathologic phenotypes and outcome in adenocarcinoma of the ampulla of Vater
    Chang, D. K.
    Johns, A.
    Scarlett, C. J.
    Pajic, M.
    Chou, A.
    Toon, C.
    Samra, J. S.
    Sutherland, R.
    Gill, A. J.
    Biankin, A. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [37] Adenocarcinoma of the ampulla of Vater - A 28-year experience
    Talamini, MA
    Moesinger, RC
    Pitt, HA
    Sohn, TA
    Hruban, RH
    Lillemoe, KD
    Yeo, CJ
    Cameron, JL
    ANNALS OF SURGERY, 1997, 225 (05) : 590 - 599
  • [38] Frequent Activation of the mTOR Pathway in Adenocarcinoma of the Ampulla of Vater
    Crowder, C. D.
    Iwenofu, O. H.
    Bellizzi, A. M.
    Frankel, W. L.
    MODERN PATHOLOGY, 2010, 23 : 353A - 353A
  • [39] Adenocarcinoma with signed ring cells of the ampulla of Vater: an uncommon pathology
    Lesquereux Martinez, Lucia
    Fernandez Perez, Aquilino
    Bustamante Montalvo, Manuel
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2012, 104 (09) : 501 - 502
  • [40] Coexistence of Large Cell Neuroendocrine Carcinoma and Adenocarcinoma of the Ampulla of Vater
    Liu, Shih-Hao
    Tsay, Shvh-Haw
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2008, 71 (10) : 536 - 540